Barclays PLC Cuts Stock Position in Novavax, Inc. (NASDAQ:NVAX)

Barclays PLC trimmed its holdings in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 41.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 413,467 shares of the biopharmaceutical company's stock after selling 296,112 shares during the quarter. Barclays PLC owned approximately 0.26% of Novavax worth $3,325,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVAX. Spire Wealth Management bought a new stake in Novavax during the 4th quarter worth approximately $29,000. New Age Alpha Advisors LLC purchased a new stake in Novavax in the 4th quarter worth $35,000. KBC Group NV lifted its position in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 3,917 shares in the last quarter. TigerOak Management L.L.C. bought a new position in shares of Novavax during the 4th quarter valued at approximately $86,000. Finally, AlphaQuest LLC lifted its position in Novavax by 290.1% during the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 7,940 shares during the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Price Performance

Shares of NVAX traded up $0.25 during mid-day trading on Wednesday, reaching $6.67. 5,233,922 shares of the company's stock traded hands, compared to its average volume of 8,367,770. The stock's 50-day moving average is $7.07 and its two-hundred day moving average is $8.27. Novavax, Inc. has a 12 month low of $4.29 and a 12 month high of $23.86. The stock has a market cap of $1.07 billion, a P/E ratio of -2.95, a P/E/G ratio of 2.85 and a beta of 3.15.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same period last year, the company earned ($1.44) EPS. Research analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on NVAX. TD Cowen raised Novavax to a "hold" rating in a research note on Thursday, February 27th. BTIG Research assumed coverage on Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.